Company profile for Innoviva

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innoviva’s portfolio includes the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (flutica...
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innoviva’s portfolio includes the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1350 Old Bayshore Highway Suite 400 Burlingame, CA 94010
Telephone
Telephone
650-238-9600
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251125545821/en/Innoviva-to-Participate-in-the-37th-Annual-Piper-Sandler-Healthcare-Conference

BUSINESSWIRE
25 Nov 2025

https://www.businesswire.com/news/home/20251105298339/en/Innoviva-Reports-Third-Quarter-2025-Financial-Results-Highlights-Recent-Company-Progress

BUSINESSWIRE
05 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-20/innoviva-specialty-therapeutics-announces-oral-presentation-featuring-new-analyses-from-the-zoliflod

PHARMIWEB
20 Oct 2025

https://www.pharmiweb.com/press-release/2025-08-26/innoviva-to-participate-in-upcoming-investor-conferences

PHARMAWEB
26 Aug 2025

https://www.businesswire.com/news/home/20250806443890/en/Innoviva-Reports-Second-Quarter-2025-Financial-Results-Highlights-Recent-Company-Progress

BUSINESSWIRE
06 Aug 2025

https://www.businesswire.com/news/home/20250612432209/en/FDA-Grants-Priority-Review-for-Zoliflodacin-New-Drug-Application-for-the-Treatment-of-Uncomplicated-Gonorrhea-and-Assigns-Target-PDUFA-Date-of-December-15-2025

BUSINESSWIRE
12 Jun 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty